We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current FYB market cap is 822.81M. The company's latest EPS is EUR 4.2927 and P/E is 8.67.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 33.86M | 34.57M | 41.65M | 42.5M | 77.7M |
| Operating Income | -2.27M | -5.74M | -13.3M | -17.73M | -369k |
| Net Income | -2.29M | -5.93M | -13.48M | 35.99M | 75.8M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 53.56M | 75.6M | 66.33M | 853.7M | 890.36M |
| Total Liabilities | 5.34M | 7.56M | 10.26M | 497.12M | 387.61M |
| Total Equity | 48.21M | 68.04M | 56.07M | 356.58M | 502.75M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -1.48M | -5.1M | -14.18M | -18.88M | -9.85M |
| Investing | -5.71M | -648k | -4.24M | -37.07M | -17.38M |
| Financing | 17.24M | 25.64M | 1.35M | 40.74M | 44.44M |
| Market Cap | 822.81M |
| Price to Earnings Ratio | 8.67 |
| Price to Sales Ratio | 8.45 |
| Price to Cash Ratio | 24.3 |
| Price to Book Ratio | 1.31 |
| Dividend Yield | - |
| Shares Outstanding | 17.66M |
| Average Volume (1 week) | 5.21k |
| Average Volume (1 Month) | 3.18k |
| 52 Week Change | -26.15% |
| 52 Week High | 67.80 |
| 52 Week Low | 37.65 |
| Spread (Intraday) | 0.6 (1.27%) |
| Company Name | Formycon AG |
| Address |
fraunhoferstr. 15 munich D 82152 |
| Website | https://www.formycon.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
